This Is What Whales Are Betting On Vertex Pharmaceuticals

Someone with a lot of money to spend has taken a bearish stance on Vertex Pharmaceuticals VRTX.

And retail traders should know.

We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with VRTX, it often means somebody knows something is about to happen.

So how do we know what this whale just did?

Today, Benzinga's options scanner spotted 11 uncommon options trades for Vertex Pharmaceuticals.

This isn't normal.

The overall sentiment of these big-money traders is split between 27% bullish and 72%, bearish.

Out of all of the special options we uncovered, 7 are puts, for a total amount of $370,215, and 4 are calls, for a total amount of $238,067.

Today's Best Finance Deals

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $340.0 to $370.0 for Vertex Pharmaceuticals over the last 3 months.

Volume & Open Interest Development

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale activity within a strike price range from $340.0 to $370.0 in the last 30 days.

Vertex Pharmaceuticals Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Where Is Vertex Pharmaceuticals Standing Right Now?

• With a volume of 457,847, the price of VRTX is up 0.18% at $350.15.
• RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
• Next earnings are expected to be released in 31 days.

What The Experts Say On Vertex Pharmaceuticals:

• Cantor Fitzgerald downgraded its action to Overweight with a price target of $370

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.